Exclusive partnership

SCHWIND eye-tech-solutions, Germany, has announced an exclusive partnership with ALPHAEON Corporation, US. SCHWIND has granted ALPHAEON the exclusive license to market SCHWIND AMARIS technology in the US. As part of the relationship, ALPHAEON will oversee and finance the US Food and Drug Administration (FDA) clinical trial required to market the product in the US. ALPHAEON, a wholly-owned subsidiary of Strathspey Crown Holdings LLC, closely cooperates with American eye surgeons to bring highly developed technologies to the US market. SCHWIND chief executive officer Rolf Schwind (pictured) said: “This cooperation is a historical milestone in the SCHWIND company history and for us, as a medium-sized family company, the best possible strategy to establish our cutting-edge technology in North America without entrepreneurial risks. We strongly believe that our partnership with ALPHAEON will build customer confidence and significantly impact the growth of patient procedures.”
www.eye-tech-solutions.com
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.